Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

10.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
1.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inpatient Stress Test Modality and Downstream Clinical Pathways in Troponin-Negative Patients: A Real-World Cohort Study.

Cureus·2026
Same author

Growing teratoma syndrome of the ovary: a case series.

Journal of medical case reports·2026
Same author

Erratum: Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Androgen activity in the male embryonic hindbrain drives lethal PFA ependymoma.

Nature·2026
Same author

Phase I study of niraparib with radiotherapy for treatment of metastatic and locally advanced invasive carcinoma of the cervix (NIVIX).

Frontiers in oncology·2026
Same author

Immunotherapy approaches for the treatment of relapsed or progressive medulloblastoma.

Journal of neuro-oncology·2026

Related Experiment Video

Updated: Mar 31, 2026

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
04:25

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

12.0K

Risk-Based Therapy for Localized Osteosarcoma.

Rajkumar Venkatramani1, Jeffrey Murray2, Lee Helman3

  • 1Department of Pediatrics, Baylor College of Medicine, Texas Children's Cancer Center, Texas Children's Hospital, Houston, Texas.

Pediatric Blood & Cancer
|October 27, 2015
PubMed
Summary
This summary is machine-generated.

Intensifying chemotherapy for localized osteosarcoma with high-dose melphalan and cyclophosphamide did not improve survival rates. Standard chemotherapy demonstrated superior event-free and overall survival in patients with poor histological response.

Keywords:
clinical trialshigh-dose chemotherapynecrosisosteosarcomastem cell transplantation

More Related Videos

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
09:25

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

19.8K
A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

4.4K

Related Experiment Videos

Last Updated: Mar 31, 2026

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
04:25

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

12.0K
Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
09:25

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

19.8K
A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

4.4K

Area of Science:

  • Oncology
  • Surgical Oncology
  • Pediatric Oncology

Background:

  • Localized osteosarcoma outcomes have stagnated over 30 years.
  • Histological response to neoadjuvant chemotherapy is a key prognostic indicator.
  • Treatment modifications based on histological response have not enhanced survival.

Purpose of the Study:

  • To evaluate the efficacy of intensifying postoperative chemotherapy in localized osteosarcoma patients with poor histological response.
  • To determine if high-dose alkylator chemotherapy improves survival outcomes compared to standard treatment.

Main Methods:

  • Patients with localized osteosarcoma received neoadjuvant cisplatin, doxorubicin, and methotrexate.
  • Poor responders (<90% necrosis) received intensified therapy: melphalan, cyclophosphamide, and stem cell infusion.
  • Good responders (≥90% necrosis) continued standard postoperative chemotherapy.

Main Results:

  • Forty-eight percent of tumors showed good histological response.
  • High-dose chemotherapy arm showed 5-year event-free survival (EFS) of 28% and overall survival (OS) of 48%.
  • Standard chemotherapy arm showed 5-year EFS of 62% and OS of 74%; all patients on high-dose arm experienced severe hematological toxicity.

Conclusions:

  • Postoperative intensification with high-dose cyclophosphamide and melphalan did not improve survival in localized osteosarcoma.
  • Standard chemotherapy provided better survival outcomes than intensified high-dose chemotherapy for poor responders.